NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-23-295 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to invite Small Research Grant (R21) applications that propose to study the ethical, legal, and social implications (ELSI) of human genetics and genomics. Applications may propose studies using either single or mixed methods. Direct involvement of key stakeholders where appropriate is encouraged. These applications should be for small research projects, such as those that involve single investigators. Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues. This mechanism can also be used for the collection of preliminary data and the secondary analysis of existing data.
Funding Opportunity PAR-23-294 from the NIH Guide for Grants and Contracts. The purpose of this NOFO is to invite Exploratory/Developmental Research Grant (R21) applications that propose to study the ethical, legal, and social implications (ELSI) of human genetics and genomics. Applications may propose studies using either single or mixed methods. Approaches may include but are not limited to empirical qualitative and quantitative methods, as well as conceptual, legal, and normative analyses. Direct involvement of key stakeholders where appropriate is encouraged. Of particular interest are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information.
Funding Opportunity RFA-DA-25-021 from the NIH Guide for Grants and Contracts. Human immunodeficiency virus (HIV) infection is widely prevalent in individuals in the reproductive age group. Globally, an estimated 1.3 million people living with HIV (PWH) become pregnant each year (UNAIDS data, 2019). With the advent of antiretroviral therapy (ART), significant progress has been made in the prevention of vertical transmission of HIV. However, although ART has clear benefits in preventing vertical transmission, ART regimens are associated with higher rates of preterm birth, stillbirth, and early infant death. Optimal development and functioning of the placenta are key factors in maintenance of pregnancy and positively corelate with maternal and fetal outcomes. Despite this, there is considerable paucity of data on the impact of HIV/ART exposure on the placenta. Even less is known on the impact of HIV/ART exposure on the placenta in pregnant individuals with substance use/misuse.
Notice NOT-AA-24-001 from the NIH Guide for Grants and Contracts
Notice NOT-CA-24-007 from the NIH Guide for Grants and Contracts
Notice NOT-DE-23-007 from the NIH Guide for Grants and Contracts
Notice NOT-CA-24-002 from the NIH Guide for Grants and Contracts
Notice NOT-OD-24-021 from the NIH Guide for Grants and Contracts
Notice NOT-OD-24-020 from the NIH Guide for Grants and Contracts
Notice NOT-OD-24-019 from the NIH Guide for Grants and Contracts
Notice NOT-DE-24-002 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AT-24-006 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) announcement is to support the development and maintenance of a Resource Center for Cannabis and Cannabinoid Research through a cooperative agreement funding mechanism (U24). Such a Center will address challenges and barriers to conducting research on cannabis and its constituents as well as to enable researchers to successfully generate more rigorous scientific evidence across a variety of research domains in both basic and clinical research. The Center is expected to be a focal point for researchers entering the cannabis research space and to support the development and establishment of research tools and studies that will improve upon and eventually change the landscape of cannabis research. Overall, the Center will facilitate research advances through synergistic interactions among experts in relevant commercial, basic science, clinical, and regulatory areas both within the Center itself and in collaboration with the extramural community.
Notice NOT-OD-24-001 from the NIH Guide for Grants and Contracts
Funding Opportunity PAS-24-058 from the NIH Guide for Grants and Contracts. The purpose of this NIDCD initiative is to encourage research in the development, characterization, and reproducibility/reliability of human auditory and vestibular organoids.Applications investigating animal organoids are allowable but only if accompanying comparative or other integrated companion studies with human organoids. Singular animal organoid studies alone are not responsive to this funding opportunity. This funding opportunity encourages innovative, reproducible, and novel methodologies and technologies that will drive the reproducibility and holistic longevity of hearing/balance sensory organoids as model systems. The development of novel tools to deliver genes, proteins, molecules, and synthetics that might lead to the successful expansion and longer-term survivability of organoid populations in a stable, reliable, and reproducible manner is highly encouraged. Subsequent characterization of the organoid platforms must be shown to mimic and recapitulate the native correlative biological function. Applications that provide approaches that remove current barriers and lessen challenges to improve current reproducibility and stability are highly encouraged. Applications that have breakthrough approaches and technologies using human auditory/vestibular organoids are highly encouraged.
Funding Opportunity PAS-24-057 from the NIH Guide for Grants and Contracts. The purpose of this NIDCD initiative is to encourage research in the development, characterization, and reproducibility/reliability of human auditory and vestibular organoids. Proposals investigating animal organoids are allowable but only if accompanying comparative or other integrated companion studies with human organoids. Singular animal organoid studies alone are not responsive to this funding opportunity. This funding opportunity encourages innovative, reproducible, and novel methodologies and technologies that will drive the reproducibility and holistic longevity of hearing/balance sensory organoids as model systems. The development of novel tools to deliver genes, proteins, molecules, and synthetics that might lead to the successful expansion and longer-term survivability of organoid populations in a stable, reliable, and reproducible manner is highly encouraged. Subsequent characterization of the organoid platforms must be shown to mimic and recapitulate the native correlative biological function. Applications that provide approaches that remove current barriers and lessen challenges to improve current reproducibility and stability are highly encouraged. Applications that have breakthrough approaches and technologies using human auditory/vestibular organoids are highly encouraged.
Funding Opportunity RFA-AI-23-060 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to support the late-stage engineering and preclinical development of innovative biological products that safely and specifically kill HIV-infected cells. Products of interest include but are not limited to broadly neutralizing antibodies (bNAbs), their derivatives, and other soluble, antibody-like molecules.
Funding Opportunity RFA-AI-23-061 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to accelerate the development of safe and effective long-acting drug delivery systems for improved, simplified treatment of HIV-1 in children. This NOFO invites applicants engaged in the development of existing long-acting platforms at early stages of development stages to perform specific preclinical activities that enable product optimization and accelerated translation to HIV-infected children. Collaborative research partnerships with industry are required.
Notice NOT-MH-24-290 from the NIH Guide for Grants and Contracts
Notice NOT-DA-23-044 from the NIH Guide for Grants and Contracts
Notice NOT-AI-23-073 from the NIH Guide for Grants and Contracts